dr. weber discusses updated data for checkmate-238
Published 6 years ago • 202 plays • Length 1:50Download video MP4
Download video MP3
Similar videos
-
1:44
dr. weber on the updated analysis of the checkmate-238 trial in melanoma
-
1:42
dr. weber on biomarker data from checkmate-238 for melanoma
-
1:05
dr. weber on rationale for the checkmate-238 trial in melanoma
-
1:17
dr. weber on checkmate-238 compared to other trials in melanoma
-
0:56
dr. weber on checkmate-238 for melanoma
-
1:19
how the results of combi-ad and checkmate-238 will impact melanoma care
-
0:58
impact of checkmate-238 results for patients with melanoma
-
30:53
immunotherapy side effects: what patients need to know with dr. jeffery weber
-
11:47
what is stage iii melanoma?
-
1:02:36
cancer revealed: how the immune system sees and destroys tumors, with jeffrey weber
-
2:18
dr. jeffrey weber on checkmate-064 trial for advanced melanoma
-
7:04
checkmate 238: adjuvant checkpoint therapy after melanoma resection
-
0:57
dr. weber on fda approval of pembrolizumab for stage iii melanoma
-
1:15
dr. weber on nivolumab in the adjuvant setting for melanoma
-
5:44
4-year results from checkmate 238: adjuvant nivo vs ipi in resected stage iii/iv melanoma
-
1:14
dr. weber discusses advancements in melanoma
-
1:46
dr. weber on selecting immunotherapy for patients with melanoma
-
5:30
jeffrey s weber, asco 2018 – resected stage iii melanoma and the checkmate 238 trial
-
0:59
dr. weber on the fda approval for fixed-dose of nivolumab
-
7:34
adjuvant therapy for melanoma: nivolumab, pembrolizumab, ipilimumab, dabrafenib and trametinib
-
1:22
dr. weber on adjuvant pembrolizumab in melanoma
-
7:00
metastatic melanoma: the immunotherapy approach